Skip to main content
Philippe Armand, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

PhilippeArmandMD

Oncology • Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Join to view full profile

Dr. Armand is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Armand's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2001 - 2004
  • University of California San Francisco School of Medicine
    University of California San Francisco School of MedicineClass of 2000

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2022 - Present
  • MA State Medical License
    MA State Medical License 2004 - 2024
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Mass Cytometry of Hodgkin Lymphoma Reveals a CD4+ Exhausted T-effector and T-regulatory Cell Rich Microenvironment  
    David Wu, Margaret A Shipp, Jonathan R Fromm, Philippe Armand, Scott J Rodig, Blood

Abstracts/Posters

  • Comparative Genomic Analyses Defines Shared and Unique Features of cHL and PMBL and New Mechanisms of Sensitivity to PD-1 Blockade
    Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
    Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
    Philippe Armand, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Optimizing Clinical Outcomes in Blood Cancers Through Groundbreaking Translational Research 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymph... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Integrated Genetic and Topological Analysis Reveals a Hodgkin-like Mechanism of Immune Escape in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Study Sounds Note of Caution on Effectiveness of Covid Vaccines for Patients with Lymphoid Malignancies
    Study Sounds Note of Caution on Effectiveness of Covid Vaccines for Patients with Lymphoid MalignanciesAugust 24th, 2021
  • MRD in NHL: New Technologies Poised to Redefine Tx Paradigms
    MRD in NHL: New Technologies Poised to Redefine Tx ParadigmsAugust 7th, 2019
  • Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin Lymphoma
    Post-Transplant Pembrolizumab Consolidation Improves PFS in Relapsed/Refractory Hodgkin LymphomaJuly 1st, 2019
  • Join now to see all

Professional Memberships

Hospital Affiliations

Dr. Philippe Armand, Dr. Philippe Armand, MD, Dr. P Armand